Harsh Vardhan says Cadila Covid jab as safe as it gets nod for Phase-3 trial

The drug regulatory body Drugs Controller General of India (DCGI) on Sunday gave its permission to Zydus Cadila, Ahmedabad based drug firm, to initiate Phase III clinical trials of its Covid-19 vaccine ZyCoV-D.

The move came after DGCI approved Serum Institute of India’s Covishield and Bharat Biotech’s COVAXIN for emergency use.

Also Read | A year on, China is shaking up the world

“The nation’s first indigenously developed DNA vaccine candidate against COVID-19, ZyCoV-D, by M/s Zydus Cadila has been approved by Drugs Controller General of India (DCGI), for the conduct of the Phase III clinical trials,” the Ministry of Science and Technology said in a release on Sunday.

In Phase I and II, Zydus Cadila conducted clinical trials of the DNA vaccine in more than 1,000 participants and its interim data shows that the vaccine is safe and immunogenic when three doses were administered intradermally.

“Based on the recommendations of the Subject Expert Committee, which reviewed the interim data, the DCGI has accorded permission for conducting Phase-III clinical trial in 26,000 Indian participants,” the Ministry said.

Based on the interim data, Union Health Minister Harsh Vardhan took to Twitter to say ‘it’s safe’

According to Ministry, the candidate has been supported by the National Biopharma Mission (NBM) under the aegis of Biotechnology Industry Research Assistance Council (BIRAC) and the Department of Biotechnology, Ministry of Science and Technology, Government of India.

READ  World's largest drone is set to transmit 5G connectivity from the stratosphere using an antenna

Dr. Renu Swarup, Secretary, DBT and Chairperson, BIRAC, took to Twitter on Sunday to mark this major achievement.

She also said, “The establishment of the Nation’s first DNA vaccine platform is an important milestone for Atma Nirbhar Bharat and a big leap forward for Indian scientific research.

Subscribe to Mint Newsletters

* Enter a valid email

* Thank you for subscribing to our newsletter.


Leave a Reply

This website uses cookies. By continuing to use this site, you accept our use of cookies.